1. 2. 3. References Prins RM, Vo DD, Khan-Farooqi H, Yang MY, Soto H, Economou JS, et al. NK and CD4 cells col- laborate to protect against melanoma tumor forma- tion in the brain. J Immunol 2006; 177:8448-55; PMID:17142742. Wilson EH, Weninger W, Hunter CA. Trafficking of immune cells in the central nervous system. J Clin Invest 2010; 120:1368-79; PMID:20440079; http:// dx.doi.org/10.1172/JCI41911. Margolin K, Enrstoff MS, Hamid O, et al. Evaluation of ipilimumab in melanoma patients with brain metas- tases: a phase II trial. Lancet Oncol; PMID:22456429; http://dx.doi.org/10.1016/S1470-2045(12)70090-6. 4. 5. Schmittel A, Proebstle T, Engenhart-Cabillic R, Scheibenbogen C, Geueke AM, Thiel E, et al. Brain metastases following interleukin-2 plus interferon- alpha-2a therapy: a follow-up study in 94 stage IV melanoma patients. Eur J Cancer 2003; 39:476-80; PMID:12751378; http://dx.doi.org/10.1016/S0959- 8049(02)00731-1. Powell S, Dudek AZ. Single-institution outcome of high-dose interleukin-2 (HD IL-2) therapy for meta- static melanoma and analysis of favorable response in brain metastases. Anticancer Res 2009; 29:4189-93; PMID:19846971. 6. 7. Guirguis LM, Yang JC, White DE, Steinberg SM, Liewehr DJ, Rosenberg SA, et al. Safety and efficacy of high-dose interleukin-2 therapy in patients with brain metastases. J Immunother 2002; 25:82-7; PMID:11924913; http://dx.doi. org/10.1097/00002371-200201000-00009. Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U, et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablativechemoradiation preparative regimens. J Clin Oncol 2008; 26:5233-9; PMID:18809613; http://dx.doi.org/10.1200/JCO.2008.16.5449. www.landesbioscience.com OncoImmunology 1199